Purple Biotech shares are trading lower by 28% during Tuesday's session. The company announced a $2.8 million offering. Purple Biotech's Phase 2 trial of CM24 in metastatic PDAC patients showed ...

Accordingly, the stock price of the company’s shares decreases ... ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Shares of Purple Biotech Ltd (NASDAQ:PPBT ... The stock had previously closed at $4.69. Separately, HC Wainwright reaffirmed a “buy” rating and set a $33.00 price target on shares of ...

Purple Biotech PPBT, a clinical-stage oncology company, reported positive final results from the mid-stage study of its lead candidate, CM24, for treating pancreatic ductal adenocarcinoma (“PDAC ...

it received an extension of 180 calendar days from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) to regain compliance with the Nasdaq’s minimum $1.00 bid price ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...